No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ABOS Acumen Pharmaceuticals
- 2.330
- -0.170-6.80%
Close Jun 18 16:00 ET
- 2.400
- +0.070+3.00%
Post 19:24 ET
139.99MMarket Cap-2219P/E (TTM)
2.500High2.330Low408.59KVolume2.490Open2.500Pre Close986.57KTurnover1.26%Turnover RatioLossP/E (Static)60.08MShares11.31052wk High0.53P/B75.53MFloat Cap1.81052wk Low--Dividend TTM32.42MShs Float26.980Historical High--Div YieldTTM6.80%Amplitude1.810Historical Low2.414Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Accorded Launches Latest Offering, Accorded Acumen: The Actuarial Data Transformation Platform
SAN MATEO, Calif.--(BUSINESS WIRE)--Accorded, Inc., a leader in healthcare actuarial intelligence, unveils its latest offering: Accorded Acumen. Acumen is an actuarial data transformation platform tha
BTIG Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Maintains Target Price $11
BTIG analyst Thomas Shrader maintains $Acumen Pharmaceuticals(ABOS.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 37.8% and
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Buy Rating Justified: Acumen Pharmaceuticals' Promising Position in Alzheimer's Treatment Market
Express News | HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Acumen Pharmaceuticals' Sabirnetug: A Novel Approach in Alzheimer's Disease Treatment Warrants a Buy Rating
Comments
$Acumen Pharmaceuticals(ABOS.US$
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma bio...
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma bio...
$Acumen Pharmaceuticals(ABOS.US$ Acumen Pharmaceuticals Collaborates With Lonza Covering The Manufacture Of Sabirnetug (ACU193) For Alzheimer's Disease, For Clinical Development And Commercialization, If Approved
1
$Acumen Pharmaceuticals(ABOS.US$
slowly moving up
slowly moving up
2
$Acumen Pharmaceuticals(ABOS.US$ announced that it has entered into a senior secured loan and security agreement with K2 HealthVentures, a healthcare-focused specialty finance company.![]()
2
$Acumen Pharmaceuticals(ABOS.US$ Just off ATL ( you know how i likes me some bottom bouncers, hehehe ) Earnings out Monday 11/13/23 BMO! But mainly for the following! Phase 1 data on ACU193/INTERCEPT-AD was very promising! The Recent collaboration & License agreement with HALOZYME Could make this Alzheimer’s treatment a game changer for patients by allowing the delivery of the drug Subcutaneously instead of IV? Which would be much more convenient and less inva...
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg